Drug Trial Radar · NCT06663943
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
Last checked: Nov 19, 2026Latest source record: Oct 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Oct 30, 2026
Study completion Nov 1, 2026
Sponsor
- Lead sponsor
- Chao JiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pemphigus is characterized by the presence of IgG antibodies that lead to the loss of keratinocyte adhesion, resulting in blister formation. The etiology of pemphigus antibodies is multifactorial, involving immune dysregulation, genetic predisposition, and potential viral triggers. CD38, a multifunctional transmembrane glycoprotein, plays a crucial role in B-cell maturation and function. CM313, a novel humanized monoclonal antibody targeting CD38, has shown promise in clinical trials for autoimmune diseases, including refractory/relapsed multiple myeloma (RRMM), systemic lupus erythematosus (SLE), and immune thrombocytopenia (ITP). By binding to CD38 on B cells, CM313 modulates B-cell activation, proliferation, and differentiation, potentially reducing the production of autoantibodies, such as those against desmogleins 1/3 in pemphigus. Preclinical studies have demonstrated that CM313 effectively inhibits CD38 enzymatic activity through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and Fc-mediated apoptosis. The long-term modulation of B-cell-mediated immune responses by CM313, through the depletion of both short-lived and long-lived plasma cells, suggests a novel therapeutic strategy for pemphigus by targeting the production of pathogenic autoantibodies.
Conditions
- Pemphigus Disease
- Pemphigus Vulgaris (PV)
Interventions
CM313 (SC)Drug
CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
GlucocorticoidsDrug
Patients in the control group receive azathioprine in combination with steroid therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to achieve disease control(DC)Time frame: 54 weeks
- Pemphigus Disease Area Index (PDAl)Time frame: 36 week
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.